SVR Rates of Direct-Acting Antiviral Hepatitis C Therapies in Patients at a Specialty Pharmacy

Abstract

Specific Aims: To compare sustained virological response at 12 weeks after the end of therapy (SVR12) rates of direct acting antiviral (DAA) hepatitis C therapies in patients at a specialty pharmacy to SVR12 rates from recently published literature. To identify insurance coverage rates among different insurance payer types. Subjects: Patients that were at least 18 years or older, have a diagnosis of Hepatitis C, and had at least 1 DAA fill from Avella Specialty Pharmacy. Methods: A retrospective chart review was conducted utilizing data extracted from patient profiles who have filled a prescription at Avella Specialty Pharmacy for either Epclusa, Harvoni, Mavyret, Vosevi, or Zepatier during January 2017 to March 2018. Main Results: Of the 1,738 patients extracted for the review, 712 patients had SVR12 outcomes documented. The overall SVR12 rate of patients at Avella Specialty Pharmacy was not significantly different from published literature (97% vs 97%, p=0.96). Patients with genotype 2 at Avella Specialty Pharmacy achieved a total higher SVR12 rate when compared to published literature (100% vs 96%, p<0.05). Medicare had the highest coverage rates and Medicaid had the lowest coverage rates (56% and 16%, respectively). Conclusions: Our findings show that Avella Specialty Pharmacy can help patients obtain high cost medications through their insurance while maintaining SVR12 rates similar to those published in the literature. The services provided to patients by specialty pharmacies are essential to maintain high treatment outcomes and improve coverage rates.